2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.76 USD
-0.17 (-3.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.75 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TSVT 4.76 -0.17(-3.45%)
Will TSVT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSVT
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Other News for TSVT
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
Leerink Partners Sticks to Their Buy Rating for 2seventy bio (TSVT)
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Bristol-Myers posts Q1 beat despite growth headwinds